Benchmark Capital Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Benchmark Capital Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$902K	Sell	25,000 -8,500	-25%	-$399K	0.9%	38
2018 Q3	$2.06M	Sell	33,500 -1,500	-4%	-$96.4K	1.55%	16
2018 Q2	$2.36M	Buy	35,000 +5,400	+18%	+$302K	1.79%	13
2018 Q1	$1.61M	Hold	29,600	–	–	1.27%	22
2017 Q4	$1.77M	Buy	29,600 +200	+0.7%	+$12.1K	1.38%	23
2017 Q3	$1.43M	Buy	29,400 +16,000	+119%	+$873K	1.11%	27
2017 Q2	$704K	Sell	13,400 -35,925	-73%	-$1.67M	0.56%	50
2017 Q1	$2.24M	Sell	49,325 -11,800	-19%	-$526K	1.77%	18
2016 Q4	$2.31M	Sell	61,125 -2,075	-3%	-$78.5K	1.92%	16
2016 Q3	$2.38M	Buy	63,200 +8,500	+16%	+$187K	1.8%	15
2016 Q2	$963K	Buy	54,700 +4,200	+8%	+$68K	0.79%	42
2016 Q1	$614K	Sell	50,500 -5,300	-9%	-$83.9K	0.54%	54
2015 Q4	$1.36M	Sell	55,800 -500	-0.9%	-$11.7K	1.15%	28
2015 Q3	$999K	Buy	56,300 +900	+2%	+$16.3K	0.81%	42
2015 Q2	$978K	Buy	55,400 +37,700	+213%	+$691K	0.69%	46
2015 Q1	$555K	Sell	17,700 -31,200	-64%	-$904K	0.37%	71
2014 Q4	$1.43M	Buy	48,900 +1,900	+4%	+$48.2K	0.96%	30
2014 Q3	$972K	Buy	+47,000	New	+$927K	0.67%	49

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Benchmark Capital Advisors's AERI Position: Q4 2018 in Review

Benchmark Capital Advisors reduced its Aerie Pharmaceuticals (AERI) stake by 25% in Q4 2018, selling an estimated $399K and leaving 25,000 shares worth $902K. The position accounts for 0.9% of the portfolio, ranked #38.

Benchmark Capital Advisors first reported a position in AERI in Q3 2014 and has held it in 18 quarters since. The position peaked at $2.38M in Q3 2016. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Benchmark Capital Advisors held 25,000 shares of Aerie Pharmaceuticals worth $902K as of Q4 2018.
Benchmark Capital Advisors sold 8,500 Aerie Pharmaceuticals shares in Q4 2018, an estimated $399K.
Aerie Pharmaceuticals made up 0.9% of Benchmark Capital Advisors's portfolio in Q4 2018, its #38 holding.
Benchmark Capital Advisors first reported a position in Aerie Pharmaceuticals in Q3 2014 and has held it in 18 quarters since.
Benchmark Capital Advisors's Aerie Pharmaceuticals position peaked at $2.38M in Q3 2016.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.